Nursing and Health Professions
Systematic Review
100%
Metastatic Colorectal Cancer
100%
Cancer Therapy
83%
Patient
66%
Bevacizumab
58%
Glucose
33%
Prescription
33%
Diabetes Mellitus
33%
Gender
30%
Chemotherapy
28%
Survival
27%
Overall Survival
27%
Toxicity
27%
Confidence Interval
25%
Analysis
25%
Drug
21%
Hazard Ratio
19%
Clinical Practice
11%
Adverse Event
11%
Progression Free Survival
8%
Health Service
8%
Synthesis
8%
Data Base
8%
Sodium
6%
Female
6%
Metformin
6%
Outpatient
6%
Medicine and Dentistry
Meta-Analysis
100%
Metastatic Colorectal Cancer
66%
Therapeutic Procedure
50%
Cancer Treatment
50%
Observational Study
38%
Maturity Onset Diabetes of the Young
33%
Patient with Type 2 Diabetes
33%
Association
33%
Glucose
33%
Drug Prescription
33%
Patient
33%
Overall Survival
27%
Toxicity
27%
Survival
27%
Chemotherapy
22%
Age
21%
Subgroup Analysis
19%
Hazard Ratio
19%
Chemotherapeutic Agent
18%
Drug
18%
Inpatient
16%
Adverse Event
11%
Progression Free Survival
8%
Hope
8%
Health Care
8%
Glycon
6%
Prescribing Drug
6%
Sodium
6%
Cross Sectional Study
6%
FOLFIRI
6%
Analysis
5%
Decision Making
5%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Colorectal Cancer
66%
Bevacizumab
58%
Malignant Neoplasm
50%
Glucose
33%
Chemotherapy
33%
Prescription Drug
33%
Non Insulin Dependent Diabetes Mellitus
33%
Toxicity
27%
Overall Survival
27%
Survival
27%
Drug
21%
Randomized Clinical Trial
16%
Sodium Glucose Cotransporter 2
12%
Thiazolidinedione
12%
Adverse Event
11%
Observational Study
11%
Dipeptidyl Peptidase IV Inhibitor
8%
Progression Free Survival
8%
Sodium
6%
Cohort Study
6%
Random Effects Model
6%
Metformin
6%
Sulfonylurea
6%
